Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
296
-
Total 13F shares, excl. options
-
54.2M
-
Shares change
-
+528K
-
Total reported value, excl. options
-
$4.05B
-
Value change
-
+$50.2M
-
Put/Call ratio
-
0.24
-
Number of buys
-
159
-
Number of sells
-
-150
-
Price
-
$74.61
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q2 2025
366 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q2 2025.
HAEMONETICS CORP - Common Stock (HAE) has 296 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.2M shares
.
Largest 10 shareholders include BlackRock, Inc. (6.36M shares), VANGUARD GROUP INC (4.95M shares), NEUBERGER BERMAN GROUP LLC (4.28M shares), WELLINGTON MANAGEMENT GROUP LLP (2.15M shares), STATE STREET CORP (1.88M shares), River Road Asset Management, LLC (1.66M shares), T. Rowe Price Investment Management, Inc. (1.59M shares), ROYCE & ASSOCIATES LP (1.27M shares), GEODE CAPITAL MANAGEMENT, LLC (1.24M shares), and Capital Research Global Investors (1.14M shares).
This table shows the top 296 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.